Fig. 1
hOM-MSCs ameliorate EAE better than hBM-MSCs when administered during severe disease. a EAE clinical course after i.v. injection of 1 × 106 hOM-MSCs (n = 5) or 1 × 106 hBM-MSCs (n = 6) or PBS (n = 6) during early disease. Both hOM- and hBM-MSCs ameliorated EAE to a similar extent. b EAE clinical course after i.v. injection of 1 × 106 hOM-MSCs (n = 14) or 1 × 106 hBM-MSCs (n = 10) or PBS (n = 12) during severe disease. hOM-MSCs significantly ameliorated disease whilst hBM-MSCs did not (*p < 0.05, 2-way ANOVA with Tukey’s multiple comparison). c Individual linear regression lines fitted through severe disease animal EAE curves showed hOM-MSC treated animals have significantly steeper slopes compared to PBS animals. d Comparison of the coefficients confirmed significantly faster improvements in hOM-MSC injected animals compared with control, hBM-MSC injected animals had no significant difference (*p < 0.05, Kruskal–Wallis, Dunn’s multiple comparison test). e hOM-MSC treated animals had a significant reduction in cumulative disease scores and f the area under the curve (AUC) compared to PBS controls (*p < 0.05, ANOVA Tukey’s multiple comparison). g hOM-MSC injected animals had a faster recovery of pre-disease weight compared to PBS controls (*p < 0.05, **p < 0.01 2-way ANOVA with Tukey’s multiple comparison). h There were no significant differences in the distribution of animal score between the treatment groups